Z
Zhenfei Li
Researcher at Chinese Academy of Sciences
Publications - 25
Citations - 922
Zhenfei Li is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 11, co-authored 19 publications receiving 726 citations. Previous affiliations of Zhenfei Li include Cleveland Clinic Lerner Research Institute & Laboratory of Molecular Biology.
Papers
More filters
Journal ArticleDOI
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Zhenfei Li,Andrew C. Bishop,Mohammad Alyamani,Jorge A. Garcia,Robert Dreicer,Dustin R. Bunch,JJ Liu,Sunil K. Upadhyay,Richard J. Auchus,Nima Sharifi +9 more
TL;DR: It is proposed that direct treatment with D4A would be more clinically effective than abiraterone treatment, because competitive androgen receptor antagonism by D2A is comparable to the potent antagonist enzalutamide and D3A also has more potent anti-tumour activity against xenograft tumours than abIRaterone.
Journal ArticleDOI
Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation
TL;DR: It is shown that Wnt3a specifically stimulates H4K20 monomethylation at the T cell factor (TCF)-binding element through the histone methylase SET8, which indicates that H 4K20me-1 is a marker for gene transcription activation, at least in canonical Wnt signaling.
Journal ArticleDOI
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Zhenfei Li,Mohammad Alyamani,Jianneng Li,Kevin Rogacki,Mohamad E. Abazeed,Sunil K. Upadhyay,Steven P. Balk,Mary-Ellen Taplin,Richard J. Auchus,Nima Sharifi +9 more
TL;DR: The findings suggest a previously unappreciated and biochemically specific method of clinically fine-tuning abiraterone metabolism to optimize therapy, and demonstrate the specific biochemical effects of pharmacological 5α-reductase inhibition on abiraters metabolism.
Journal ArticleDOI
Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
Jianneng Li,Mohammad Alyamani,Mohammad Alyamani,Ao Zhang,Kai Hsiung Chang,Michael Berk,Zhenfei Li,Ziqi Zhu,Marianne Petro,Cristina Magi-Galluzzi,Mary-Ellen Taplin,Jorge A. Garcia,Kevin D. Courtney,Eric A. Klein,Nima Sharifi +14 more
TL;DR: It is shown that enzalutamide treatment in human models of prostate cancer and patient tissues is accompanied by a ubiquitin E3-ligase, AMFR, mediating loss of 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2), which otherwise inactivates cortisol, sustaining tumor cortisol concentrations to stimulate GR and enzyme resistance.
Journal ArticleDOI
Smurf1-mediated Lys29-linked Nonproteolytic Polyubiquitination of Axin Negatively Regulates Wnt/β-catenin Signaling
Cong Fei,Zhenfei Li,Chen Li,Yuelei Chen,Zhangcheng Chen,Xiaoli He,Li Mao,Xin Wang,Rong Zeng,Lin Li +9 more
TL;DR: A novel function of Smurf1 is reported in regulating Wnt/β-catenin signaling through targeting axin for nonproteolytic ubiquitination through Lys 29 (K29)-linked polyubiquitin chains.